Nguyen Nghia, Bellile Emily, Thomas Daffyd, McHugh Jonathan, Rozek Laura, Virani Shama, Peterson Lisa, Carey Thomas E, Walline Heather, Moyer Jeffery, Spector Matthew, Perim Daniel, Prince Mark, McLean Scott, Bradford Carol R, Taylor Jeremy M G, Wolf Gregory T
Department of Otolaryngology, University of Michigan Medical School, Ann Arbor, Michigan.
Center for Cancer Biostatistics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan.
Head Neck. 2016 Jul;38(7):1074-84. doi: 10.1002/hed.24406. Epub 2016 Feb 16.
Because immune responses within the tumor microenvironment are important predictors of tumor biology, correlations of types of tumor infiltrating lymphocytes (TILs) with clinical outcomes were determined in 278 patients with head and neck squamous cell carcinoma (HNSCC).
Infiltrating levels of CD4 (helper T cells), CD8 (cytotoxic/suppressor T cells), FoxP3 (regulatory T cells), CD68 (myeloid-derived suppressor cells,) and CD1a (Langerhans) cells were measured in tissue microarrays (TMAs). Cox models tested associations with patient outcomes after adjusting for all known prognostic factors. Median follow-up was 36.6 months.
Higher CD4 and CD8 TIL levels were associated with improved overall survival (OS; hazard ratio [HR] = 0.77; 95% confidence interval [CI] = 0.65-0.93; p = .005 and HR = 0.77; 95% CI = 0.64-0.94; p = .008, respectively), and relapse-free survival (RFS; p = .03 and .05, respectively). After controlling for prognostic factors, higher CD4 levels predicted improved OS and disease-specific survival (DSS; p = .003 and p = .004, respectively).
The findings suggest that TILs are a significant independent prognostic factor for HNSCC that differ by treatment. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1074-1084, 2016.
由于肿瘤微环境中的免疫反应是肿瘤生物学的重要预测指标,因此在278例头颈部鳞状细胞癌(HNSCC)患者中确定了肿瘤浸润淋巴细胞(TILs)类型与临床结局的相关性。
在组织微阵列(TMA)中测量CD4(辅助性T细胞)、CD8(细胞毒性/抑制性T细胞)、FoxP3(调节性T细胞)、CD68(髓源性抑制细胞)和CD1a(朗格汉斯细胞)的浸润水平。Cox模型在调整所有已知预后因素后测试与患者结局的关联。中位随访时间为36.6个月。
较高的CD4和CD8 TIL水平与总生存期(OS)改善相关(风险比[HR]=0.77;95%置信区间[CI]=0.65-0.93;p=0.005和HR=0.77;95%CI=0.64-0.94;p=0.008),以及无复发生存期(RFS;分别为p=0.03和0.05)。在控制预后因素后,较高的CD4水平预测OS和疾病特异性生存期(DSS)改善(分别为p=0.003和p=0.004)。
研究结果表明,TILs是HNSCC的一个重要独立预后因素,且因治疗而异。©2016威利期刊公司。《头颈》38:1074-1084,2016年。